Lead Product(s): Certolizumab Pegol
Therapeutic Area: Immunology Product Name: Cimzia
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
EMA has approved a label extension for CIMZIA for use in adult patients with axial spondyloarthritis (axSpA) at a reduced maintenance dose of 200 mg every four weeks, once sustained remission is achieved after one year of CIMZIA 200 mg every two weeks or 400 mg.